Improving cancer biopsy testing accuracy with new standards and software
Official title: FY24 SBIR PHASE II RD CONTRACT - TOPIC 442 BOSTON CELL STANDARDS, INC.
Funded at Boston Cell Standards INC · NIH-11219741 · Data updated 2026-11-12
This study is working to make cancer biopsy tests more accurate so that patients can get reliable results no matter where their tests are done, helping doctors make better treatment decisions.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston Cell Standards INC NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | September 16, 2024 |
| Project end | September 15, 2026 |
| Funding year | 2024 |
| Award (this year) | $1,995,119 |
| NIH project number | 75N91024C00087-0-9999-1 |
| Project ID | NIH-11219741 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are cancer patients undergoing biopsy testing that requires immunohistochemistry analysis.
✕Less likely to help
Patients who are not undergoing biopsy testing or those whose treatment does not involve immunohistochemistry may not benefit from this research.
What this research studies
This research aims to enhance the accuracy of immunohistochemistry (IHC) testing for cancer biopsies, which is crucial for proper diagnosis and treatment. The project will develop reference standards and software to reduce error rates in test results, which currently range from 10-30%. By creating a standardized approach, the research seeks to ensure that patients receive consistent and reliable test outcomes, regardless of the laboratory performing the analysis. The project will involve multiple stages, including improvements in calibrator manufacturing and the development of a database for laboratory performance comparison.
Why it matters
Potential benefit: If successful, this research could lead to more accurate cancer diagnoses and better-targeted treatments for patients.
How similar studies have gone: Other research has shown success in improving diagnostic accuracy through standardization, making this approach promising and relevant.
Where this research is happening
-
Boston Cell Standards INC
Boston, United States Active
Researchers
- Principal investigator: Bogen, Steve — Boston Cell Standards INC
- Study coordinator: Bogen, Steve
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.